Clinical trials: Cerebrovascular Disorder
Transcranial Bone Marrow Injection, RK-4
RK-4 Intracalvariosseous Injection in Treatment of Acute Large Hemispheric Infarction
An open-label, blinded Ib/IIa study investigating the treatment of acute large hemispheric infarction by transcranial bone marrow injection of RK-4 injection For subjects with acute large hemispheric infarction who are…
- Conditions
- Transcranial Bone Marrow Injection, RK-4, Acute Large Hemispheric Infarction, Acute Ischemic Stroke
- Trial name
- NCT07166380
- Testing
- RK-4 injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Neurodawn Pharmaceutical Co., Ltd.
Stroke, Broca's Aphasia
Assessment of Cortical Stimulation Combined With Rehabilitation to Enhance Recovery in Broca's Aphasia.
The primary objective of this feasibility study is to evaluate the safety and effectiveness of targeted sub-threshold epidural cortical stimulation delivered concurrent with speech-language rehabilitation activities to enhance…
- Trial name
- NCT00170703
- Testing
- Cortical Electrical Stimulation
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Northstar Neuroscience
Atrial Fibrillation
Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs…
- Trial name
- NCT03462446
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonists (VKAs)
- Where
- Spain
- Volunteers
- 249 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Hybernia Medical Post-Mechanical Thrombectomy Cerebral Cooling in Stroke
Reducing the temperature of tissue or organs (hypothermia) produces a protective state, through multiple molecular mechanisms, against adverse effects that arise from disrupted organ blood flow, e.g.
- Trial name
- Post-MECC (NCT06634303)
- Testing
- Brain cooling
- Where
- Spain
- Volunteers
- 8 people
- Sponsor
- Hybernia Medical
Ischemic Stroke
Cerebrolysin REGistry Study in Stroke
Investigation of clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with acute ischemic stroke.
- Trial name
- CREGS-S (NCT02541227)
- Testing
- Cerebrolysin
- Where
- Austria
- Volunteers
- 1,823 people
- Sponsor
- Ever Neuro Pharma GmbH
Ischemic Stroke
Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)
The purpose of this pivotal study is to demonstrate safety and effectiveness of the NeuroThera® Laser System (referred to hereafter as NTS) in the treatment of Subjects diagnosed with acute ischemic stroke.
- Trial name
- NCT00419705
- Testing
- NeuroThera® Laser System
- Where
- 58 sites in United States, Germany and 2 more
- Volunteers
- 660 people
- Sponsor
- PhotoThera, Inc
Intracranial Aneurysm
Safety and Efficacy Analysis of FRED™/FRED™Jr Embolic Device in Aneurysm Treatment
A prospective, multicenter, observational evaluation of the safety and efficacy of the FRED® device in the treatment of intracranial aneurysms
- Trial name
- NCT03423290
- Testing
- FRED and FRED Jr
- Where
- 7 sites in United Kingdom
- Volunteers
- 61 people
- Sponsor
- Microvention-Terumo, Inc.
Non-valvular Atrial Fibrillation (NVAF)
A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under…
- Trial name
- XARIN (NCT03887780)
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939)
- Where
- India
- Volunteers
- 504 people
- Sponsor
- Bayer
Ischemic Stroke
Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment…
- Trial name
- SONIC (NCT02831088)
- Testing
- Neu2000KWL High-does group, Neu2000KWL Low-does group
- Where
- 6 sites in South Korea
- Volunteers
- 210 people
- Sponsor
- GNT Pharma
Ischemic Stroke
The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke.
- Trial name
- CASTA (NCT00868283)
- Testing
- Cerebrolysin, 0.9% Saline Solution
- Where
- 49 sites in China, Hong Kong and 1 more
- Volunteers
- 1,071 people
- Sponsor
- Ever Neuro Pharma GmbH
Acute Ischemic Stroke
DAISe 1 Feasibility Study to Evaluate the DAISe Thrombectomy System for Acute Ischemic Stroke
The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 36 subjects. The maximum enrollment is 10 subjects per site. A maximum of 6 investigational centers in Europe will participate.
- Trial name
- NCT05139147
- Testing
- DAISe Thrombectomy System
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- MIVI Neuroscience, Inc.
Carotid Stenosis, Atherosclerosis
Revacept in Symptomatic Carotid Stenosis
Patients suffering from symptomatic carotid artery stenosis, transient ischemic attacks (TIAs), amaurosis fugax or stroke receive either Revacept (single dose) plus antiplatelet monotherapy or monotherapy alone.
- Conditions
- Carotid Stenosis, Atherosclerosis, Stroke, Transient-ischaemic Attack
- Trial name
- RevaceptCS02 (NCT01645306)
- Testing
- Revacept
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 158 people
- Sponsor
- AdvanceCor GmbH
Acute Ischemic Stroke
First-in-man Study of the Cerebrovascular Interventional Procedural Control System
The objective of this study the first human use of a new device in treatment of acute ischemic stroke, which to evaluate the feasibility, safety, and efficacy of the Cerebrovascular Interventional Procedural Control System.
- Trial name
- NCT05972252
- Testing
- Cerebrovascular Interventional Procedural Control System
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Dinova Neuroscience Technology Co., Ltd
Stroke
Rehabilitation of the Stroke Hand at Home
The purpose of this research is to evaluate a therapy delivery system for stroke patients that provide accessible, affordable stroke care.
- Trial name
- HAAPI (NCT01144715)
- Testing
- Hand Mentor (TM) robotic stroke therapy device, Home Therapy Program
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Kinetic Muscles
Acute Ischemic Stroke, Intracranial Stenosis
Acandis Credo Intracranial Stent for Unsuccessful Recanalization After Thrombectomy (ACUTE)
Study objective is to evaluate the efficacy and safety of acute permanent stenting of symptomatic intracranial stenosis following unsuccessful recanalization by thrombectomy in acute ischemic stroke with large vessel occlusion…
- Trial name
- ACUTE (NCT03955835)
- Testing
- Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.
- Where
- 8 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Acandis GmbH
Postoperative Complications, Memory Disorders
A Study to Determine if Carbon Dioxide Lavage During Total Knee Surgery Reduces Intraoperative Embolic Events
The purpose of this study is to determine if the use of a carbon dioxide lavage device (CarboJet) to clean bone surfaces during total knee surgery decreases intraoperative embolic events when compared with standard orthopedic…
- Trial name
- NCT00736125
- Testing
- pulsatile saline lavage, carbon dioxide lavage
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kinamed Incorporated
Fabry Disease
Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease
This was a multinational, open-label study to assess the efficacy and safety of AVR-RD-01 in approximately 15 male subjects, who were 16 years of age or older and postpubertal with a confirmed diagnosis of classic Fabry disease…
- Trial name
- NCT03454893
- Testing
- AVR-RD-01
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 15 people
- Sponsor
- AVROBIO
Fabry Disease
A Study of Fabrazyme in Pediatric Patients With Fabry Disease
People with Fabry disease have an alteration in their genetic material (DNA) which causes a deficiency of the a-galactosidase A enzyme.
- Trial name
- NCT00074958
- Testing
- Fabrazyme (agalsidase beta)
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Cerebral Hemorrhage, Intraventricular Hemorrhage
Active Removal of IntraCerebral Hematoma Via Active Irrigation
Study evaluating if active irrigation by IRRAflow® with infusion of tPA will reduce the time needed for clearance of intracerebral and intraventricular hemorrhage compared with passive drainage.
- Trial name
- ARCH (NCT05118997)
- Testing
- IRRAflow, EVD
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- IRRAS
Acute Ischemic Stroke
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study.
- Trial name
- ACTISAVE (NCT05070260)
- Testing
- Intravenous glenzocimab (ACT017) 1000 mg
- Where
- 10 sites in United States, Germany
- Volunteers
- 438 people
- Sponsor
- Acticor Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.